Theralink Technologies is a proteomics-based, precision medicine company with a nationally CLIA-certified and CAP-accredited laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and laboratory developed tests (LDTs), Theralink’s technology targets multiple areas of oncology and drug development. In addition to the Company’s first assay for advanced breast cancer, Theralink is actively working on a second assay that is planned to be pan-tumor for solid tumors across multiple tumor types such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal, lung, prostate, among others. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, help reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
Company profile
Ticker
THER
Exchange
Website
CEO
Brian Barnett
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OncBioMune Pharmaceuticals, Inc, PediatRx Inc., QUINT MEDIA INC., Striker Energy Corp
SEC CIK
Corporate docs
Subsidiaries
OncBioMune, Inc. ...
IRS number
202590810
THER stock data
Latest filings (excl ownership)
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
6 Mar 24
10-Q
2024 Q1
Quarterly report
20 Feb 24
10-K/A
2023 FY
Annual report (amended)
15 Feb 24
NT 10-Q
Notice of late quarterly filing
15 Feb 24
10-K
2023 FY
Annual report
5 Jan 24
NT 10-K
Notice of late annual filing
29 Dec 23
8-K
Other Events
27 Nov 23
10-Q
2023 Q3
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
8-K
Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer
29 Jun 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Apr 23 | Jeffrey Busch | Common Stock Purchase Warrant Common Stock | Grant | Acquire A | No | No | 0.003 | 44,314,286 | 132.94 k | 44,314,286 |
22 Apr 23 | Jeffrey Busch | 10% O.I.D. Senior Secured Convertible Debenture Common Stock | Grant | Acquire A | No | No | 141000 | - | 155.10 k | - |
29 Nov 22 | Matthew Wilson Schwartz | Common Stock Purchase Warrant Common Stock | Other | Acquire J | No | No | 0.003 | 4,201,681 | 12.61 k | 4,201,681 |
29 Nov 22 | Matthew Wilson Schwartz | Common Stock Purchase Warrant Common Stock | Other | Acquire J | No | No | 0.003 | 34,571,111 | 103.71 k | 34,571,111 |
29 Nov 22 | Matthew Wilson Schwartz | 8% Convertible Promissory Note Common Stock | Other | Dispose J | No | No | 0.0048 | - | 105.22 k | - |
29 Nov 22 | Matthew Wilson Schwartz | 10% O.I.D. Senior Secured Convertible Debenture Common Stock | Other | Acquire J | No | No | 0.003 | - | 121.00 k | - |
29 Nov 22 | Danica Holley | Common Stock Purchase Warrant Common Stock | Other | Acquire J | No | No | 0.003 | 2,100,840 | 6.30 k | 2,100,840 |
29 Nov 22 | Danica Holley | Common Stock Purchase Warrant Common Stock | Other | Acquire J | No | No | 0.003 | 17,029,905 | 51.09 k | 17,029,905 |
29 Nov 22 | Danica Holley | 8% Convertible Promissory Note Common Stock | Other | Dispose J | No | No | 0.0048 | - | 51.83 k | - |
29 Nov 22 | Danica Holley | 10% O.I.D. Senior Secured Convertible Debenture Common Stock | Other | Acquire J | No | No | 0.003 | - | 59.60 k | - |